EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Approach to the Patient: Insulinoma

Johannes Hofland iD, Julie C Refardt iD, Richard A Feelders iD, Emanuel Christ iD, Wouter W de Herder iD

The Journal of Clinical Endocrinology & Metabolism · 15.03.2024 · 109 (4) · 1109-1118

DOI: 10.1210/clinem/dgad641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.10.2023. Verfasst von Johannes Hofland und 4 weiteren Autor:innen. Beteiligte Einrichtung: ENETS Center of Excellence, Department of Internal Medicine, Section of Endocrinology, Erasmus MC and Erasmus MC Cancer Institute, 3015 GD Rotterdam,…. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms, Hypoglycemia, Neuroendocrine Tumors. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare. Most insulinomas present with the Whipple triad: (1) symptoms, signs, or both consistent with hypoglycemia; (2) a low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to normal. Nonmetastatic insulinomas are nowadays referred to as “indolent” and metastatic insulinomas as “aggressive.” The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100%; for patients with an aggressive insulinoma, this amounts to 24% to 67%. Five percent to 10% of insulinomas are associated with the multiple endocrine neoplasia type 1 syndrome. Localization of the insulinoma and exclusion or confirmation of metastatic disease by computed tomography is followed by endoscopic ultrasound or magnetic resonance imaging for indolent, localized insulinomas. Glucagon-like peptide 1 receptor positron emission tomography/computed tomography or positron emission tomography/magnetic resonance imaging is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas. Supportive measures and somatostatin receptor ligands can be used for to control hypoglycemia. For single solitary insulinomas, curative surgical excision remains the treatment of choice. In aggressive malignant cases, debulking procedures, somatostatin receptor ligands, peptide receptor radionuclide therapy, everolimus, sunitinib, and cytotoxic chemotherapy can be valuable options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaPancreatic NeoplasmsHypoglycemiaNeuroendocrine TumorsHumansReceptors, Somatostatin

Stichwörter der Autor:innen

hypoglycemiainsulininsulinomapathologytherapy

Substanzen

Receptors, Somatostatin

Autor:innen und Institutionen

  • ENETS Center of Excellence, Department of Internal Medicine, Section of Endocrinology, Erasmus MC and Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • ENETS Center of Excellence, Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, CH-4031 Basel, Switzerland.

ORCID-Profile: Johannes Hofland, Julie C Refardt, Richard A Feelders, Emanuel Christ, Wouter W de Herder

Zitieren

APA

Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024). Approach to the Patient: Insulinoma. The Journal of Clinical Endocrinology & Metabolism, 109(4), 1109-1118. https://doi.org/10.1210/clinem/dgad641

Vancouver

Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the Patient: Insulinoma. The Journal of Clinical Endocrinology & Metabolism. 2024;109(4):1109-1118. doi:10.1210/clinem/dgad641

BibTeX
@article{Hofland2024,
  author = {Hofland, Johannes and Refardt, Julie C and Feelders, Richard A and Christ, Emanuel and de Herder, Wouter W},
  title = {Approach to the Patient: Insulinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {4},
  pages = {1109--1118},
  doi = {10.1210/clinem/dgad641}
}
Kostenlos starten →